AstraZeneca boss Pascal Soriot was last night at the centre of an extraordinary row among City investors over his multi-million-pound bonus. The French chief executive has been lauded for rolling out Astra's life-saving Covid vaccine at no profit, as well as fighting off predatory buyers and boosting the company's share price since he took charge in 2012. But Astra's major shareholders are understood to have been locked in heated talks for days after the drugs giant proposed to boost his bonus and performance-related share award by £2.
Important Legal Notice about News Sources: Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news and we may not share the views of the author or publisher. We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.
Important Investment Notice: The value of investments can fall and you may get back less than you invested. Past performance is not a reliable indicator of future returns. There is no guarantee that the tax efficient nature of any investment product mentioned within this website will remain. Investments may not be suitable for everybody and potential investors are recommended to seek independent advice based on your personal circumstances before investing. The information provided on this website is intended for UK residents only. By continuing to use this website you confirm that you have the necessary right to do so. In particular the information provided does not constitute an offer to sell or buy securities for the benefit of any US resident or US person.
Important Cookie Notice: We use browser cookies to ensure you get the best user experience from our website. If you continue without changing your browser cookie settings, we will assume that you are happy to receive all cookies from this website. For further information, please read our Privacy and Cookies Policy.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
Important Legal Notice about News Sources
Pilling and Co Stockbrokers Ltd. is not responsible for the content or accuracy of third party news articles and we may not share the views of the author or publisher.
We provide third party news for your convenience and information only and make no representation or endorsement whatsoever and hereby exclude all liability for any loss or damage that may be incurred by you as a result of your access or use. Please note that third party content may be subject to terms and conditions imposed by the third party owner of that content.
